Archive: Company News
Eisbach Bio Receives EUR 8 Million Government Grant to Progress COVID-19 Antiviral Through Phase I/II Clinical Development
Eisbach Bio, a biotechnology company targeting the molecular machines that drive human disease, today announced additional financial support from the German Ministry for Education and Research (BMBF) for the clinical development of its first-in-class SARS-CoV-2 helicase inhibitor. The total funding of EUR 8 million will support the clinical development of the Company’s novel COVID-19 therapeutic following the recent completion of its preclinical development.
Adept Neuro Reaches Key Milestone in the Development of Novel Intracerebral Stereoelectroencephalography (SEEG) Electrodes
— Second investment tranche provided by DIXI medical
— Preparation of regulatory certifications and market launch
Adept Neuro SA (Lausanne, Switzerland), a joint venture of DIXI Medical (Le Locle, Switzerland, and Besançon, France) and Aleva Neurotherapeutics SA (Lausanne, Switzerland) developing a new generation of intracerebral stereoelectroencephalography (SEEG) electrodes facilitating localization and thermocoagulation of the epileptogenic zones, today announced that it has reached a significant milestone in the development of MEMS-enabled smart SEEGs electrodes. MEMS are micro-electro-mechanical systems allowing for miniaturization and great flexibility of design.
BellaSeno Initiates Scaffold Development Program for Tendon and Ligament Regeneration
— Collaboration with Fraunhofer IZI further expanded
— Funding provided by Sächsische Aufbaubank
BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that the Company has initiated a program on tendon and ligament reconstruction funded by the State of Saxony´s Sächsische Aufbaubank (SAB). The program will be run in close collaboration with Fraunhofer Institute for Cell Therapy and Immunology (Fraunhofer IZI), which will be responsible for the development of an animal model for subsequent in vivo performance testing of the scaffolds.
Cardior Pharmaceuticals: Pioneering Study Confirms Pivotal Role of Antisense microRNA Approach in the Treatment of Pathologic Hypertrophy of the Heart
— First-ever data on therapeutic miR-132 inhibition in a large animal model of nonischemic heart failure with cardiac hypertrophy and fibrosis
— Peer-reviewed publication in the Journal of the American College of Cardiology
Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that results from a recent peer-reviewed study underlining the Company´s pioneering approach in the treatment of cardiac diseases were published in the Journal of the American College of Cardiology. The data confirm that the inhibition of the naturally occurring miR-132 microRNA via an antisense microRNA can prevent pathological cardiac remodeling in hypertrophic heart disease.